High-density lipoprotein cholesterol targeting for novel drug discovery: Where have we gone wrong?

Expert Opinion on Drug Discovery

Volumn 9, Issue 2, 2014, Pages 119-124

  Escolà Gil, Joan Carles ^a,b,c   Cedó, Lídia ^a,b   Blanco Vaca, Francisco ^a,b,c  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

ApoA I; Cardiovascular disease; Cholesteryl ester transfer protein inhibitors; High density lipoprotein

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ABC TRANSPORTER G5; ABC TRANSPORTER G8; ANACETRAPIB; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG TARGETING; GENETIC ASSOCIATION; HEART INFARCTION; HEART PROTECTION; HUMAN; MACROPHAGE; NONHUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DRUG DISCOVERY; HUMANS;

EID: 84893045521     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.871257     Document Type: Review

References (18)

1. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007;298:786-98
2. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
3. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010;153:800-8
4. Degoma EM, Rader DJ. Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 2011;8:266-77
5. Escola-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. In vivo macrophagespecific RCT and antioxidant and antiinflammatory HDL activity measurements: new tools for predicting HDL atheroprotection. Atherosclerosis 2009;206:321-7
6. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
7. Ginsberg HN, Reyes-Soffer G. Niacin: a long history, but a questionable future. Curr Opin Lipidol 2013;24:475-9
8. Balder JW, Staels B, Kuivenhoven JA. Pharmacological interventions in human HDL metabolism. Curr Opin Lipidol 2013;24:500-9
9. Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res 2012;53:1755-66
10. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80
11. Nordestgaard BG, Tybjaerg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. Curr Opin Lipidol 2011;22:113-22
12. Khera AV, Patel PJ, Reilly MP, Rader DJ. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol 2013;62:1909-10
13. Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2012;32:2813-20
14. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011;364:127-35
15. Li XM, Tang WH, Mosior MK, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013;33:1696-705
16. Rosenson RS, Brewer HB Jr, Ansell B, et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 2013;128:1256-67
17. Watson CE, Weissbach N, Kjems L, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 2011;52:361-73
18. Lee-Rueckert M, Blanco-Vaca F, Kovanen PT, Escola-Gil JC. The role of the gut in reverse cholesterol transport - focus on the enterocyte. Prog Lipid Res 2013;52:317-28